|
Targeted Gene Therapy for Lymphoma
|
5R01CA113454-03
|
$256,177
|
$256,177
|
SMITH, BRUCE
|
AUBURN UNIVERSITY AT AUBURN
|
|
Bay Area Tumor Institute CCOP
|
5U10CA045461-19
|
$481,201
|
$9,624
|
Feusner, James
|
BAY AREA TUMOR INSTITUTE
|
|
SV40 Pathogenesis of Human Infections
|
5R01CA104818-05
|
$467,229
|
$186,892
|
BUTEL, JANET
|
BAYLOR COLLEGE OF MEDICINE
|
|
Contributions of Epstein-Barr Virus EBNA2 and EBNA-LP to B cell immortalization
|
5F31CA126523-02
|
$35,140
|
$17,570
|
Echendu, Chisaroka
|
BAYLOR COLLEGE OF MEDICINE
|
|
Enhancing T Cell Therapy of Cancer
|
2P01CA094237-06
|
$1,905,870
|
$133,411
|
Heslop, Helen
|
BAYLOR COLLEGE OF MEDICINE
|
|
SPORE in Lymphoma
|
5P50CA126752-02
|
$2,266,618
|
$1,133,309
|
Heslop, Helen
|
BAYLOR COLLEGE OF MEDICINE
|
|
Role of PML nuclear body proteins for establishment of EBV latent infection
|
5R01CA124309-03
|
$258,530
|
$258,530
|
Ling, Paul
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-02S1
|
$117,286
|
$4,691
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-02
|
$1,515,000
|
$60,600
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Mechanism and Consequences of Telomere Dysfunction
|
1R01CA133249-01
|
$318,513
|
$159,257
|
Songyang, Zhou
|
BAYLOR COLLEGE OF MEDICINE
|
|
Novel Strategies for Immunotherapy of Cancer
|
5R01CA101795-05
|
$263,284
|
$157,970
|
Wang, Rongfu
|
BAYLOR COLLEGE OF MEDICINE
|
|
A Pull-Push Strategy for Lymphoma Immunotherapy
|
5K08CA105064-05
|
$128,547
|
$128,547
|
Song, Wenru
|
BAYLOR RESEARCH INSTITUTE
|
|
Virginia Mason Community Clinical Oncology Program
|
5U10CA035192-25
|
$453,250
|
$9,065
|
Vuky, Jacqueline
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
Training Patients and Partners for HSCT: A Novel Coping Skills Intervention
|
5R03CA130725-02
|
$84,500
|
$42,250
|
Lawsin, Catalina
|
BERNARD M. BARUCH COLLEGE
|
|
Eastern Cooperative Oncology Group
|
5U10CA080775-10
|
$128,678
|
$6,434
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Reconstitution of T cell immunity after UCB transplantation: The role of Treg
|
1R21CA123855-01A2
|
$391,915
|
$195,958
|
BOUSSIOTIS, VASSILIKI
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Expression and Function of Tob in T Lymphocytes
|
7R01CA104596-04
|
$318,352
|
$127,341
|
BOUSSIOTIS, VASSILIKI
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
BIDMC Research Training Grant in Cancer Radiology
|
5T32CA059367-14
|
$139,719
|
$27,944
|
CLOUSE, MELVIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Role of POZ-zinc finger proteins in hemopoietic malignacies
|
7R01CA102142-05
|
$330,443
|
$165,222
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Multistep Lymphomagenesis/Tumorigenesis in Transgenic Mice: Protein Kinase Ck2
|
5R01CA071796-11
|
$275,767
|
$137,884
|
SELDIN, DAVID
|
BOSTON MEDICAL CENTER
|
|
Transformation of Cells by the REL Oncogene
|
3R01CA047763-20S1
|
$10,000
|
$10,000
|
GILMORE, THOMAS
|
BOSTON UNIVERSITY
|
|
Transformation of Cells by the REL Oncogene
|
5R01CA047763-21
|
$275,637
|
$275,637
|
GILMORE, THOMAS
|
BOSTON UNIVERSITY
|
|
Proteomic biomarkers for lymphoma
|
5R03CA128006-02
|
$81,250
|
$81,250
|
DENIS, GERALD
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Role of P80 pro-IL-16 in T Cell Malignancy
|
5R01CA100925-04
|
$282,526
|
$141,263
|
ZHANG, YUJUN
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Epstein-Barr Virus Nuclear Proteins in B Cell Growth Transformation
|
5R01CA047006-21
|
$543,770
|
$271,885
|
KIEFF, ELLIOTT
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
SPORE in Skin Cancer
|
2P50CA093683-06A2
|
$2,300,000
|
$460,000
|
KUPPER, THOMAS
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Aspartame Intake and the Risk of Cancer
|
5R03CA130054-02
|
$116,957
|
$38,596
|
SCHERNHAMMER, EVA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Pathogenesis of Epstein-Barr Virus Infection
|
5R01CA068051-13
|
$407,881
|
$285,517
|
WANG, FREDERICK
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Coordinate Suppression of B Cell Lymphoma by PTEN and SHIP
|
1F32CA132350-01
|
$49,646
|
$49,646
|
Miletic Sedy, Ana
|
BURNHAM INSTITUTE FOR MEDICAL RESEARCH
|
|
Inflammation-regulated microRNA in B cell lymphoma
|
1R01CA135531-01
|
$381,207
|
$381,207
|
RICKERT, ROBERT
|
BURNHAM INSTITUTE FOR MEDICAL RESEARCH
|
|
CANCER CENTER SUPPORT GRANT
|
5P30CA030199-28
|
$3,649,220
|
$72,984
|
VUORI, KRISTIINA
|
BURNHAM INSTITUTE FOR MEDICAL RESEARCH
|
|
Multimodal Diagnostic and Therapeutic Nanoparticles for Non-Hodgkin's Lymphoma
|
1R43CA134046-01
|
$204,344
|
$204,344
|
CARTIERA, MALGORZATA
|
CARIGENT THERAPEUTICS
|
|
Carle Cancer Center Community Clinical Oncology Program
|
2U10CA035195-25
|
$855,703
|
$8,557
|
ROWLAND, KENDRITH
|
CARLE CLINIC ASSOCIATION, P C
|
|
Eastern Cooperative Oncology Group Studies
|
5U10CA014548-34
|
$417,899
|
$20,895
|
AVERBOOK, BRUCE
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Non-natural Nucleoside Inhibitors of DNA Polymerases
|
5R01CA118408-04
|
$229,214
|
$114,607
|
BERDIS, ANTHONY
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Mechanism of Steroid Action in Lymphoid Malignancy
|
5R01CA042755-22
|
$311,299
|
$155,650
|
DISTELHORST, CLARK
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
|
2U01CA062502-15
|
$751,074
|
$7,511
|
DOWLATI, AFSHIN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-18S3
|
$234,254
|
$16,398
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-19S1
|
$72,416
|
$5,069
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-19S2
|
|
$0
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
5P30CA043703-19
|
$5,104,000
|
$357,280
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Molecular Targeting of Bcl-xL Pathway in Cancer
|
5R01CA109181-05
|
$265,033
|
$66,258
|
HALDAR, SUBRATA
|
CASE WESTERN RESERVE UNIVERSITY
|
|
T Cell Immunity in Endemic Burkitt Lymphoma
|
1R01CA134051-01A2
|
$485,971
|
$485,971
|
MOORMANN, ANN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Cedar Rapids Oncology Project
|
2U10CA052352-19
|
$575,627
|
$5,756
|
WIESENFELD, MARTIN
|
CEDAR RAPIDS ONCOLOGY PROJECT
|
|
C-N-, and L-MYC Effects on Hematopoietic Cells
|
5R01CA078259-09
|
$231,309
|
$231,309
|
Prochownik, Edward
|
CHILDREN'S HOSP PITTSBURGH/UPMC HLTH SYS
|
|
RhoH GTPase in Hematopoiesis and Cancer
|
7R01CA113969-04
|
$316,480
|
$79,120
|
WILLIAMS, DAVID
|
CHILDREN'S HOSPITAL BOSTON
|
|
Rac GTPases as Targets in Lymphomagenesis
|
5R01CA125658-02
|
$285,000
|
$142,500
|
ZHENG, YI
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
|
Molecular Pathways in Suppression and Development of T Lineage Lymphomas
|
5R01CA125195-02
|
$312,629
|
$312,629
|
BASSING, CRAIG
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
|
USE OF mTOR INHIBITORS IN B CELL LEUKEMIA
|
5R01CA102646-04
|
$311,617
|
$102,834
|
GRUPP, STEPHAN
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
|
PSYCHOLOGICAL OUTCOME IN CHILDHOOD CANCER SURVIVORS
|
5R01CA106928-05
|
$344,888
|
$34,489
|
KAZAK, ANNE
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
Total relevant funding to Non Hodgkins Lymphoma for this search: $122,611,027
|